Clinicopathological predictor factors of axillary involvement in patients with metastatic breast cancer in the sentinel lymph node;Fatores clínico-patológicos de predição do acometimento axilar em pacientes com metástases de câncer de mama no linfonodo sentinela

Revista Brasileira de Ginecologia e Obstetricia

Volumn 32, Issue 3, 2010, Pages 144-149

  Barbosa, Edison Mantovani ^a   Francisco, Alice Aparecida Rodrigues Ferreira ^a   Araujo Neto, Joaquimteodoro de Teodoro ^a   Alves, Eloá Muniz de Freitas ^a   Tavares, Márcia Garrido Modesto ^b   Góes, João Carlos Sampaio ^a  

^a Instituto Brasileiro de Controle do Cancer   (Brazil)

^b Instituto Brasileiro de Controle do Cancer   (Brazil)

Author keywords

Breast neoplasms; Isolated tumor cells; Neoplasm invasiveness; Neoplasm metastasis; Recurrence; Sentinel lymph node biopsy

Indexed keywords

EID: 77953631256     PISSN: 01007203     EISSN: None     Source Type: Journal    
DOI: 10.1590/s0100-72032010000300008     Document Type: Article

References (28)

1. Fisher B, Bauer M, Wickerham DL, Redmond CK, Fisher ER, Cruz AB, et al. Relation of number of positive axillary nodes to the prognosis of patients with primary breast cancer. An NSABP update. Cancer. 1983;52(9):1551-7.
2. Barros ACSD, Barbosa EM, Gebrim LH, Anelli A, Figueira Filho A, Del Giglio A, et al. Diagnóstico e tratamento do câncer de mama. In: Associação Médica Brasileira. Conselho Federal de Medicina. Projeto diretrizes. Brasília: AMB/CFM; 2001. p. 1-15.
3. Lyman GH, Giuliano AE, Somerfield MR, Benson AB 3rd, Bodurka DC, Burstein HJ, et al. American Society of Clinical Oncology guideline recommendation for sentinel lymph node biopsy in early-stage breast cancer. J Clin Oncol. 2005;23(30):7703-20.
4. Mansel RE, Fallowfield L, Kissin M, Goyal A, Newcombe RG, Dixon JM, et al. Randomized multicenter trial of sentinel node biopsy versus standard axillary treatment in operable breast cancer: The ALMANAC trial. J Natl Cancer Inst. 2006;98(9):599-609.
5. Quadros LGA, Gebrim LH. A pesquisa do linfonodo sentinela para o câncer de mama na prática clínica do ginecologista brasileiro: revisão. Rev Bras Ginecol Obstet. 2007;29(3)158-64.
6. Veronesi U, Galimberti V, Mariani L, Gatti G, Paganelli G, Viale G, et al. Sentinel node biopsy in breast cancer: early results in 953 patients with negative sentinel node biopsy and no axillary dissection. Eur J Cancer. 2005;41(2):231-7.
7. Singletary SE, Allred C, Ashley P, Bassett LW, Berry D, Bland KI, et al. Revision of the American Joint Committee on Cancer staging system for breast cancer. J Clin Oncol. 2002;20(17):3628-36.
8. Singletary SE, Greene FL, Sobin LH. Classification of isolated tumor cells: clarification of the 6th edition of the American Joint Committee on Cancer Staging Manual. Cancer. 2003;98(12):2740-1.
9. McGuckin MA, Cummings MC, Walsh MD, Hohn BG, Bennett IC, Wright RG. Occult axillary node metastases in breast cancer: their detection and prognostic significance. Br J Cancer. 1996;73(1):88-95.
10. Tan LK, Giri D, Hummer AJ, Panageas KS, Brogi E, Norton L, et al. Occult axillary node metastases in breast cancer are prognostically significant: results in 368 node-negative patients with 20-years follow-up. J Clin Oncol. 2008;26(11):1803-9.
11. Martin RC 2nd, Chagpar AB, Scoggins CR, Edwards MJ, Hagendoorn L, Stromberg AJ, et al. Clinicopathologic factors associated with false-negative sentinel lymph-node biopsy in breast cancer. Ann Surg. 2005;241(6):1005-12.
12. Bleiweiss IJ, Nagi CS, Jaffer S. Axillary sentinel lymph nodes can be falsely positive due to iatrogenic displacement and transport of benign epithelial cells in patients with breast carcinoma. J Clin Oncol. 2006;24(13):2013-8.
13. Chen SL, Hoehne FM, Giuliano AE. The prognostic significance of micrometastases in breast cancer: a SEER population-based analysis. Ann Surg Oncol. 2007 14(12):3378-84.
14. Colleoni M, Rotmensz N, Peruzzotti G, Maisonneuve P, Mazzarol G, Pruneri G, et al. Size of breast cancer metastases in axillary lymph nodes: clinical relevance of minimal lymph node involvement. J Clin Oncol. 2005;23(7):1379-89.
15. de Boer M, van Deurzen CH, van Dijck JA, Borm GH, van Diese PJ, Adang EM, et al. Micrometastase or isolated tumor cells and the outcome of breast cancer. N Engl J Med. 2009;361(7): 653-63.
16. Gobardhan PD, Elias SG, Madsen EV, Bongers V, Ruitenberg HJ, Perre CI, et al. Prognostic value of micrometastases in sentinel lymph nodes of patients with breast carcinoma: a cohort study. Ann Oncol. 2009;20(1):41-8.
17. Kahn HJ, Hanna WM, Chapman JA, Trudeau ME, Lickley HL, Mobbs BG, et al. Biological significance of occult micrometastases in histologically negative axillary lymph nodes in breast cancer patients using the recent American Joint Committee on Cancer breast cancer staging system. Breast J. 2006;12(4):294-301.
18. Maibenco DC, Dombi GW, Kau TY, Severson RK. Significance of micrometastases on the survival of women with T1 breast cancer. Cancer. 2006;107(6):1234-9.
19. van Deurzen CH, Bult P, de Boer M, Koelemij R, van Hillegersberg R, Tjan-Heijnen VC, et al. Morphometry of isolated tumor cells in breast cancer sentinel lymph nodes: metastases or displacement? Am J Surg Pathol. 2009;33(1):106-10.
20. Reed J, Rosman M, Verbanac KM, Mannie A, Cheng Z, Tafra L. Prognostic implications of isolated tumor cells and micrometastases in sentinel nodes of patients with invasive breast cancer: 10-year analysis of patients enrolled in the prospective East Carolina University/Anne Arundel Medical Center Sentinel Node Multicenter Study. J Am Coll Surg. 2009;208(3):333-40.
21. Chu KU, Turner RR, Hansen NM, Brennan MB, Bilchik A, Giuliano AE. Do all patients with sentinel node metastasis from breast carcinoma need complete axillary node dissection? Ann Surg. 1999;229(4):536-41.
22. Turner RR, Chu KU, Qi K, Botnick LE, Hansen NM, Glass EC, et al. Pathologic features associated with nonsentinel lymph node metastases in patients with metastatic breast carcinoma in a sentinel lymph node. Cancer. 2000;89(3):574-81.
23. Hwang RF, Krishnamurthy S, Hunt KK, Mirza N, Ames FC, Feig B, et al. Clinicopathologic factors predicting involvement of nonsentinel axillary in women with breast cancer. Ann Surg Oncol. 2003;10(3):248-54.
24. Kohrt HE, Olshen RA, Bermas HR, Goodson WH, Wood DJ, Henry S, et al. New models and online calculator for predicting non-sentinel lymph node status in sentinel lymph node positive breast cancer patients. BMC Cancer. 2008;8:66.
25. Van Zee KJ, Manasseh DM, Bevilacqua JL, Boolbol SK, Fey JV, Tan LK, et al. A nomogram for predicting the likelihood of additional nodal metastases in breast cancer patients with a positive sentinel node biopsy. Ann Surg Oncol. 2003;10(10):1140-51.
26. Degnim AC, Griffith KA, Sabel MS, Hayes DF, Cimmino VM, Diehl KM, et al. Clinicopathologic features of metastasis in nonsentinel lymph nodes of breast carcinoma patients. Cancer. 2003;98(11):2307-15.
27. Viale G, Maiorano E, Pruneri G, Mastropasqua MG, Valentini S, Galimberti V, et al. Predicting the risk for additional axillary metastases in patients with breast carcinoma and positive sentinel lymph node biopsy. Ann Surg. 2005;241(2):319-25.
28. Langer I, Marti WR, Guller U, Moch H, Harder F, Oertli D, et al. Axillary recurrence rate in breast cancer patients with negative sentinel node (SLN) or SLN micrometastases: prospective analysis of 150 patients after SLN biopsy. Ann Surg. 2005;241(1):152-8.